Photys Therapeutics raises $75M in Series A funds to control disease-causing proteins

Photys Therapeutics has debuted with a $75 million Series A funding round. The startup focuses on phosphorylation-inducing chimeric small molecules (PHICS) — a new class of bifunctional medicines that can direct and repair protein phosphorylation.